Technical Analysis for ACOR - Acorda Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 14.35 -0.28% -0.04
ACOR closed down 0.28 percent on Tuesday, March 19, 2019, on 77 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical ACOR trend table...

Date Alert Name Type % Chg
Mar 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.28%
Mar 18 Outside Day Range Expansion -0.28%
Mar 15 Shooting Star Candlestick Bearish -1.91%
Mar 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.91%
Mar 15 Pocket Pivot Bullish Swing Setup -1.91%
Mar 15 Narrow Range Bar Range Contraction -1.91%
Mar 15 NR7 Range Contraction -1.91%
Mar 15 NR7-2 Range Contraction -1.91%
Mar 15 Up 3 Days in a Row Strength -1.91%
Mar 15 Up 4 Days in a Row Strength -1.91%

Older signals for ACOR ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS under the Fampyra name internationally. In addition, it is developing Diazapam Nasal Spray, which is in NDA preparations for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase II clinical trials for cerebral palsy and post-stroke deficits; AC105, which is in Phase II clinical trials for the treatment of SCI and TBI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for SCI. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Chemistry Health Biopharmaceutical Antibodies Autoimmune Diseases Clinical Trial Multiple Sclerosis Central Nervous System Disorders Heart Failure Spinal Cord Injury Treatment Of Heart Failure
Is ACOR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 36.35
52 Week Low 12.55
Average Volume 935,041
200-Day Moving Average 20.9626
50-Day Moving Average 15.2028
20-Day Moving Average 14.0565
10-Day Moving Average 14.112
Average True Range 0.6727
ADX 14.15
+DI 22.8699
-DI 26.099
Chandelier Exit (Long, 3 ATRs ) 14.0219
Chandelier Exit (Short, 3 ATRs ) 14.5681
Upper Bollinger Band 15.2181
Lower Bollinger Band 12.8949
Percent B (%b) 0.63
BandWidth 16.527585
MACD Line -0.1956
MACD Signal Line -0.3207
MACD Histogram 0.1251
Fundamentals Value
Market Cap 668.06 Million
Num Shares 46.6 Million
EPS -0.94
Price-to-Earnings (P/E) Ratio -15.27
Price-to-Sales 2.27
Price-to-Book 1.76
PEG Ratio 0.51
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.00
Resistance 3 (R3) 15.04 14.88 14.89
Resistance 2 (R2) 14.88 14.71 14.85 14.85
Resistance 1 (R1) 14.61 14.61 14.53 14.57 14.82
Pivot Point 14.45 14.45 14.41 14.42 14.45
Support 1 (S1) 14.18 14.28 14.10 14.14 13.88
Support 2 (S2) 14.02 14.18 13.99 13.85
Support 3 (S3) 13.75 14.02 13.81
Support 4 (S4) 13.71